To appraise the clinical and cost-effectiveness of pemigatinib within its marketing authorisation for cholangiocarcinoma.
Status In progress
Process STA 2018
ID number 3740

Provisional Schedule

Expected publication 25 August 2021

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors Incyte (pemigatinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups AMMF – The Cholangiocarcinoma Charity
Professional groups Association of Cancer Physicians
  British Society of Gastroenterology
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
16 June 2021 Committee meeting: 2
05 May 2021 - 26 May 2021 Appraisal consultation
13 April 2021 Committee meeting: 1
05 June 2020 Invitation to participate
27 March 2020 - 28 April 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 January 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance